MapLight Therapeutics, Inc. (MPLT) Stock Forecast
MPLT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.53 / 5 from 15 analysts
- Price target
- $26.54 average of analyst targets
- Upside to target
- +244.7% from the latest close
- Next earnings
- December 3, 2026 EPS estimate $-1.22
- 52-week range
- $7.70 – $39.80
MPLT analyst ratings
15 analystsNumber of analysts at each rating.
MPLT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MPLT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.17 | −$1.36 | −$1.06 | — | — | 8 |
| Current fiscal year (2026) | −$4.70 | −$5.08 | −$4.13 | −$18.56 | +74.7% | 7 |
| Next fiscal year (2027) | −$3.42 | −$5.19 | −$0.10 | −$4.70 | +27.3% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MPLT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 13 |
| Next fiscal year (2027) | $15.4M | $0 | $200.0M | 0.0% | 13 |
MPLT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MPLT revenue: reported and forecast
MPLT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.26 | −$1.23 | −$1.09 | −$1.09 | −$1.17 | −7.4% | 4 up · 0 down |
| Current fiscal year (2026) | −$5.14 | −$5.03 | −$4.64 | −$4.64 | −$4.70 | −8.6% | 5 up · 0 down |
| Next fiscal year (2027) | −$3.74 | −$3.67 | −$3.30 | −$3.30 | −$3.42 | −8.6% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MPLT earnings surprises
Reported EPS vs the consensus estimate for the last 5 quarters; MPLT beat in 1 of 5.
What analysts expect from MPLT
15 analysts cover MapLight Therapeutics; their consensus rating is strong buy (4.53 on a 1–5 scale, where 5 is a strong buy). The average price target is $26.54, 244.7% above the latest close of $7.70. Analysts expect earnings of −$4.70 per share for 2026, +74.7% from a year earlier. For 2027 the average estimate is −$3.42 per share on revenue of $15.4 million. MapLight Therapeutics beat the EPS estimate in 1 of the last 5 quarters.
Related: MPLT income statement, MPLT key metrics, MPLT chart. See the MPLT stock overview for the latest quote and news.
MPLT forecast FAQ
What is MapLight Therapeutics's price target?
The average analyst price target for MapLight Therapeutics is $26.54, 244.7% above the latest close of $7.70.
Is MapLight Therapeutics a buy, hold or sell?
Of 15 analysts covering MapLight Therapeutics, 11 rate it a strong buy, 1 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is MapLight Therapeutics's EPS forecast?
Analysts forecast −$4.70 per share for 2026 (range −$5.08 to −$4.13); for 2027 the estimate is −$3.42.
When does MapLight Therapeutics report earnings?
MapLight Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 3, 2026; the EPS estimate is $-1.22.
Does MapLight Therapeutics usually beat earnings estimates?
MapLight Therapeutics reported EPS at or above the analyst estimate in 1 of the last 5 quarters.